Log In
Print
BCIQ
Print
Print this Print this
 

MOR00208, MOR208 (formerly XmAb5574)

  Manage Alerts
Collapse Summary General Information
Company Xencor Inc.
DescriptionFc-optimized human mAb against CD19
Molecular Target CD19
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$13.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today